- Home
- IMNM vs FRSX Comparison
IMNM vs FRSX Comparison
Compare IMNM & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- FRSX
- Stock Information
- Founded
- IMNM 2006
- FRSX N/A
- Country
- IMNM United States
- FRSX Israel
- Employees
- IMNM N/A
- FRSX N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- FRSX Computer Software: Prepackaged Software
- Sector
- IMNM Health Care
- FRSX Technology
- Exchange
- IMNM Nasdaq
- FRSX Nasdaq
- Market Cap
- IMNM 747.7M
- FRSX N/A
- IPO Year
- IMNM 2020
- FRSX 2017
- Fundamental
- Price
- IMNM $12.85
- FRSX $0.67
- Analyst Decision
- IMNM Strong Buy
- FRSX
- Analyst Count
- IMNM 4
- FRSX 0
- Target Price
- IMNM $28.75
- FRSX N/A
- AVG Volume (30 Days)
- IMNM 801.6K
- FRSX 38.7K
- Earning Date
- IMNM 11-07-2024
- FRSX 11-20-2024
- Dividend Yield
- IMNM N/A
- FRSX N/A
- EPS Growth
- IMNM N/A
- FRSX N/A
- EPS
- IMNM N/A
- FRSX N/A
- Revenue
- IMNM $10,784,000.00
- FRSX $666,000.00
- Revenue This Year
- IMNM N/A
- FRSX N/A
- Revenue Next Year
- IMNM N/A
- FRSX N/A
- P/E Ratio
- IMNM N/A
- FRSX N/A
- Revenue Growth
- IMNM 62.73
- FRSX 86.55
- 52 Week Low
- IMNM $6.93
- FRSX $0.63
- 52 Week High
- IMNM $30.96
- FRSX $2.10
- Technical
- Relative Strength Index (RSI)
- IMNM 39.69
- FRSX 38.28
- Support Level
- IMNM $12.24
- FRSX $0.67
- Resistance Level
- IMNM $13.91
- FRSX $0.73
- Average True Range (ATR)
- IMNM 0.85
- FRSX 0.03
- MACD
- IMNM -0.23
- FRSX 0.00
- Stochastic Oscillator
- IMNM 16.67
- FRSX 12.47
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.